StemRIM
4599.TTSE GROWTHPharmaceutical
Financials · Standalone
| Fiscal year ended | 2025-07 | 2024-07 | 2023-07 | 2022-07 | 2021-07 | 2020-07 |
|---|---|---|---|---|---|---|
| Revenue | — | — | ¥2.4bn | ¥23m | ¥1.4bn | ¥2.1bn |
| Operating income | −¥2.0bn | −¥2.1bn | ¥142m | −¥2.0bn | −¥594m | — |
| Ordinary income | −¥2.0bn | −¥2.1bn | ¥145m | −¥2.0bn | −¥584m | ¥361m |
| Total assets | ¥7.5bn | ¥9.1bn | ¥10.7bn | ¥9.6bn | ¥10.9bn | ¥11.3bn |
| Net assets / equity | ¥7.3bn | ¥8.9bn | ¥10.4bn | ¥9.4bn | ¥10.7bn | ¥10.9bn |
| Operating cash flow | −¥1.4bn | −¥1.9bn | ¥1.1bn | −¥1.4bn | −¥520m | ¥575m |
| EPS (basic) | ¥-31.16 | ¥-32.98 | ¥2.8 | ¥-32.92 | ¥-10.02 | ¥6.44 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 13
| Period | Form | Figures |
|---|---|---|
| 2025-08-01 → 2026-01-31 | Half-year | 59 figures · EDINET |
| 2024-08-01 → 2025-07-31 | Annual | 105 figures · EDINET |
| 2024-08-01 → 2025-01-31 | Half-year | 61 figures · EDINET |
| 2023-08-01 → 2024-07-31 | Annual | 108 figures · EDINET |
| 2023-08-01 → 2024-04-30 | Quarterly Q3 | 41 figures · EDINET |
| 2023-08-01 → 2024-01-31 | Quarterly Q2 | 62 figures · EDINET |
| 2023-08-01 → 2023-10-31 | Quarterly Q1 | 38 figures · EDINET |
| 2022-08-01 → 2023-07-31 | Annual | 108 figures · EDINET |
| 2022-08-01 → 2023-04-30 | Quarterly Q3 | 40 figures · EDINET |
| 2022-08-01 → 2023-01-31 | Quarterly Q2 | 61 figures · EDINET |
| 2022-08-01 → 2022-10-31 | Quarterly Q1 | 37 figures · EDINET |
| 2021-08-01 → 2022-07-31 | Annual | 106 figures · EDINET |
| 2021-08-01 → 2022-04-30 | Quarterly Q3 | 39 figures · EDINET |
12 more reports are still being processed.